Cyclodextrin–VEGF Stem Cell Composition for Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for neurodegenerative diseases, such as Niemann-Pick disease, Alzheimer's disease, and Parkinson's disease, have limitations in effectively improving disease symptoms, and there is a need for new therapeutic strategies that can normalize neuronal function and reduce lipid and cholesterol accumulation in the brain.
Innovation Solution
A pharmaceutical composition combining cyclodextrin or its pharmaceutically acceptable salt with stem cells overexpressing vascular endothelial growth factor (VEGF) is administered to treat neurodegenerative diseases, enhancing lifespan, mobility, and reducing neurogenic inflammation and lipid accumulation in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for neurodegenerative diseases, then disease management is maintained, but effective improvement of disease symptoms is limited
Solution Approach 1:
The patent combines cyclodextrin and VEGF-overexpressed stem cells into a single pharmaceutical composition, creating a synergistic therapeutic effect that addresses multiple aspects of neurodegenerative disease simultaneously - lipid removal, neuroprotection, and angiogenesis - thereby overcoming the limitations of conventional single-agent treatments
Solution Approach 2:
The invention uses a composite therapeutic approach by formulating a pharmaceutical composition containing both cyclodextrin (for lipid chelation) and VEGF-overexpressed stem cells (for neuroprotection and angiogenesis), creating a multi-functional treatment that targets multiple disease mechanisms concurrently
2Reliability
If lipid and cholesterol accumulation is not addressed, then neurodegenerative disease progression continues, but existing treatments fail to normalize neuronal function
Solution Approach 1:
The patent employs cyclodextrin to extract and remove excess lipid and cholesterol accumulation from neuronal cells through chelation, thereby eliminating the harmful factor that drives neurodegenerative disease progression and enabling normalization of neuronal function
Solution Approach 2:
Cyclodextrin acts as an intermediary agent that facilitates the removal of lipid and cholesterol accumulation by forming inclusion complexes with these lipids, enabling their transport and elimination from affected tissues without directly damaging neuronal cells
3Reliability
If single-agent treatments are used, then treatment simplicity is maintained, but synergistic therapeutic effects are not achieved
Solution Approach 1:
The patent merges cyclodextrin and VEGF-overexpressed stem cells into a single pharmaceutical composition that can be administered together, achieving synergistic therapeutic effects while maintaining practical treatment simplicity through unified formulation and co-administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combined treatment exhibits remarkable synergistic effects, improving lifespan, mobility, inhibiting neural cell apoptosis, and reducing lipid and cholesterol accumulation in neurodegenerative disease models, particularly in Niemann-Pick disease and Alzheimer's disease.
Implementation Method 1
cyclodextrins as emerging therapeutic tools in the treatment of cholesterol-associated vascular and neurodegenerative diseases
Implementation Method 2
stem cells in which VEGF is overexpressed
Data Source
AI summary
The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative disease, containing, as active ingredients, cyclodextrin and stem cells in which VEGF is overexpressed. A combined treatment of cyclodextrin and stem cells in which VEGF is overexpressed has remarkable synergistic effects, with respect to therapeutic efficacy on the disease, such as a lifespan increase, mobility improvement, inhibition of neurogenic inflammation, inhibition of nerve cell apoptosis and inhibition of lipid accumulation in organs, including the brain, on a neurodegenerative disease model, thereby presenting a novel therapeutic strategy.